4.4 Article

Tracking Parkinson's: Study Design and Baseline Patient Data

期刊

JOURNAL OF PARKINSONS DISEASE
卷 5, 期 4, 页码 947-959

出版社

IOS PRESS
DOI: 10.3233/JPD-150662

关键词

Parkinson's disease; heterogeneity; genotype; phenotype

资金

  1. Parkinson's UK
  2. National Institute for Health Research (NIHR) DeNDRoN network
  3. NIHR Newcastle Biomedical Research Unit based at Newcastle upon Tyne Hospitals NHS Foundation Trust
  4. Newcastle University
  5. NIHR
  6. Medical Research Council [MR/L010305/1] Funding Source: researchfish
  7. Parkinson&quot
  8. s UK [J-1101] Funding Source: researchfish

向作者/读者索取更多资源

Background: There is wide variation in the phenotypic expression of Parkinson's disease (PD), which is driven by both genetic and epidemiological influences. Objectives: To define and explain variation in the clinical phenotype of PD, in relation to genotypic variation. Methods: Tracking Parkinson's is a multicentre prospective longitudinal epidemiologic and biomarker study of PD. Patients attending specialist clinics in the United Kingdom with recent onset (<3.5 years) and young onset (diagnosed <50 years of age) PD were enrolled. Motor, non-motor and quality of life assessments were performed using validated scales. Cases are followed up 6 monthly up to 4.5 years for recent onset PD, and up to 1 year for young onset PD. We present here baseline clinical data from this large and demographically representative cohort. Results: 2247 PD cases were recruited (1987 recent onset, 260 young onset). Recent onset cases had a mean (standard deviation, SD) age of 67.6 years (9.3) at study entry, 65.7% males, with disease duration 1.3 years (0.9), MDS-UPDRS 3 scores 22.9 (12.3), LEDD 295 mg/day (211) and PDQ-8 score 5.9 (4.8). Young onset cases were 53.5 years old (7.8) at study entry, 66.9% male, with disease duration 10.2 years (6.7), MDS-UPDRS 3 scores 27.4 (15.3), LEDD 926 mg/day (567) and PDQ-8 score 11.6 (6.1). Conclusions: We have established a large clinical PD cohort, consisting of young onset and recent onset cases, which is designed to evaluate variation in clinical expression, in relation to genetic influences, and which offers a platform for future imaging and biomarker research.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease

Joshua Stevenson-Hoare, Amanda Heslegrave, Ganna Leonenko, Dina Fathalla, Eftychia Bellou, Lauren Luckcuck, Rachel Marshall, Rebecca Sims, Bryan Paul Morgan, John Hardy, Bart de Strooper, Julie Williams, Henrik Zetterberg, Valentina Escott-Price

Summary: Plasma biomarkers for Alzheimer's disease-related pathologies have made significant progress in recent years, with well-validated blood tests available for the detection of amyloid and tau pathology, as well as neurodegeneration and astrocytic activation. This study demonstrates that a combination of five plasma biomarkers, along with genetic variants associated with these biomarkers, can be used to accurately diagnose and predict the onset of Alzheimer's disease.
Article Clinical Neurology

Genome-Wide Analysis of Structural Variants in Parkinson Disease

Kimberley J. Billingsley, Jinhui Ding, Pilar Alvarez Jerez, Anastasia Illarionova, Kristin Levine, Francis P. Grenn, Mary B. Makarious, Anni Moore, Daniel Vitale, Xylena Reed, Dena Hernandez, Ali Torkamani, Mina Ryten, John Hardy, Ruth W. Chia, Sonja J. Scholz, Bryan L. Traynor, Clifton J. Dalgard, Debra Ehrlich, Toshiko Tanaka, Luigi G. Ferrucci, Thomas E. Beach, Geidy P. Serrano, John J. Quinn, Vivien Bubb, Ryan L. Collins, Xuefang Zhao, Mark Walker, Emma Pierce-Hoffman, Harrison E. Brand, Michael Talkowski, Bradford Casey, Mark R. Cookson, Androo A. Markham, Mike Nalls, Medhat Mahmoud, Fritz J. Sedlazeck, Cornelis Blauwendraat, J. Raphael B. Gibbs, Andrew Singleton

Summary: By studying the genetic factors of Parkinson's disease, three structural variants associated with the risk of the disease have been discovered. This is the most comprehensive study to date of the contribution of structural variants to the genetic risk of Parkinson's disease.

ANNALS OF NEUROLOGY (2023)

Article Clinical Neurology

Functional genomics provide key insights to improve the diagnostic yield of hereditary ataxia

Zhongbo Chen, Arianna Tucci, Valentina Cipriani, Emil K. Gustavsson, Kristina Ibanez, Regina H. Reynolds, David Zhang, Letizia Vestito, Alejandro Cisterna Garcia, Siddharth Sethi, Jonathan W. Brenton, Sonia Garcia-Ruiz, Aine Fairbrother-Browne, Ana-Luisa Gil-Martinez, Nick Wood, John A. Hardy, Damian Smedley, Henry Houlden, Juan Botia, Mina Ryten

Summary: Using a systems biology approach, Chen et al. found that genes associated with adult- and child-onset ataxia share common characteristics, including a high density of short tandem repeats. Removing the age-of-onset partition and screening for repeat expansions could improve the diagnosis of hereditary ataxia.
Article Clinical Neurology

Association between the LRP1B and APOE loci and the development of Parkinson's disease dementia

Raquel Real, Alejandro Martinez-Carrasco, Regina H. Reynolds, Michael A. Lawton, Manuela M. X. Tan, Maryam Shoai, Jean-Christophe Corvol, Mina Ryten, Catherine Bresner, Leon Hubbard, Alexis Brice, Suzanne Lesage, Johann Faouzi, Alexis Elbaz, Fanny Artaud, Nigel Williams, Michele T. M. Hu, Yoav Ben-Shlomo, Donald G. Grosset, John Hardy, Huw R. Morris

Summary: Researchers performed a genome-wide survival study on almost 4000 Parkinson's disease patients and identified new genetic loci associated with faster progression to Parkinson's disease dementia, including the LRP1B receptor. Parkinson's disease is a common neurodegenerative disorder, and cognitive impairment and dementia are important features in the later stages of the disease. The genetic basis for the heterogeneity in cognitive decline among Parkinson's disease patients is not fully understood.
Article Clinical Neurology

Practically Defined Off-State Dyskinesia Following Repeated Intraputamenal Glial Cell Line-Derived Neurotrophic Factor Administration

Katherine Lloyd, Michael Lawton, Alan Whone

Summary: This study describes the increasingly prevalent pracoff-state dyskinesia during a trophic factor study, suggesting that GDNF may enable recovery of endogenous dopamine release in advanced Parkinson's disease.

MOVEMENT DISORDERS (2023)

Article Biology

Aβ efflux impairment and inflammation linked to cerebrovascular accumulation of amyloid-forming amylin secreted from pancreas

Nirmal Verma, Gopal Viswanathan Velmurugan, Edric Winford, Han Coburn, Deepak Kotiya, Noah Leibold, Laura Radulescu, Sanda Despa, Kuey C. Chen, Linda J. Van Eldik, Peter T. Nelson, Donna M. Wilcock, Gregory A. Jicha, Ann M. Stowe, Larry B. Goldstein, David K. Powel, Jeffrey H. Walton, Manuel F. Navedo, Matthew A. Nystoriak, Andrew J. Murray, Geert Jan Biessels, Claire Troakes, Henrik Zetterberg, John Hardy, Tammaryn Lashley, Florin Despa

Summary: Impairment of vascular pathways contributes to Alzheimer's disease. Blood amylin secreted from the pancreas perturbs cerebral A beta clearance, leading to amylin and A beta co-deposits in the brain microvasculature. Altering bloodborne amylin could potentially reduce cerebrovascular amylin deposits and A beta pathology.

COMMUNICATIONS BIOLOGY (2023)

Letter Clinical Neurology

Reply: Lecanemab: turning point, or status quo? An ethics perspective

John Hardy, Catherine Mummery

Editorial Material Clinical Neurology

An anti-amyloid therapy works for Alzheimer's disease: why has it taken so long and what is next?

John Hardy, Catherine Mummery

Review Clinical Neurology

Defining the Riddle in Order to Solve It: There Is More Than One Parkinson's Disease

Tiago F. Outeiro, Roy N. Alcalay, Angelo Antonini, Johannes Attems, Vincenzo Bonifati, Francisco Cardoso, Marie-Francoise Chesselet, John Hardy, Graziella Madeo, Ian McKeith, Brit Mollenhauer, Darren J. Moore, Olivier Rascol, Michael G. Schlossmacher, Hermona Soreq, Leonidas Stefanis, Joaquim J. Ferreira

Summary: Parkinson's disease is a complex syndrome with inconsistent definitions in various domains. To make breakthroughs in treatment, it is important to integrate the diverse disciplines and define the endophenotypes of typical PD accurately.

MOVEMENT DISORDERS (2023)

Article Clinical Neurology

The amyloid-β pathway in Alzheimer's disease: a plain language summary

Harald Hampel, Yan Hu, John Hardy, Kaj Blennow, Christopher Chen, George Perry, Seung Hyun Kim, Victor L. Villemagne, Paul Aisen, Michele Vendruscolo, Takeshi Iwatsubo, Colin L. Masters, Min Cho, Lars Lannfelt, Jeffrey L. Cummings, Andrea Vergallo

Summary: This summary reviews the evidence supporting the role of the amyloid-b (Ab) pathway in Alzheimer's disease (AD) and emphasizes the importance of targeting this pathway in early stages of the disease. Understanding and targeting the A beta pathway can lead to better therapeutic outcomes and management of AD.

NEURODEGENERATIVE DISEASE MANAGEMENT (2023)

Article Neurosciences

Characterization of Depressive Symptoms in Dementia and Examination of Possible Risk Factors

Lindsey Sinclair, Michael A. Lawton, Jennifer C. Palmer, Clive G. Ballard

Summary: Depression in individuals with Alzheimer's disease (AD) is common and difficult to treat, and the reasons for its occurrence are still unclear. Previous depression is the strongest risk factor for depression in AD.

JOURNAL OF ALZHEIMERS DISEASE REPORTS (2023)

Article Medicine, General & Internal

Predictors and prognosis of population-based subjective cognitive decline: longitudinal evidence from the Caerphilly Prospective Study (CaPS)

Harriet A. Ball, Elizabeth Coulthard, Mark Fish, Antony Bayer, John Gallacher, Yoav Ben-Shlomo

Summary: This study examines the association between subjective cognitive decline (sSCD) and objective cognition, finding a weak correlation between the two. Older age, poor sleep quality, and higher anxiety are independent predictors of sSCD. The study suggests that sSCD, in the absence of objective decline, may be an example of poor meta-cognition and a potential driver for functional cognitive disorder (FCD).

BMJ OPEN (2023)

Review Public, Environmental & Occupational Health

What is available to support pain management in Parkinson's: a scoping review protocol

Mark Parkinson, Cormac Ryan, Leah Avery, Annette Hand, Bhanu Ramaswamy, Julie Jones, Fiona Lindop, Monty Silverdale, Katherine Baker, Jenni Naisby

Summary: This scoping review aims to examine the available evidence on pain management in Parkinson's, with a focus on behavioural interventions, resources, and professional support for self-management. The review will analyze both quantitative and qualitative data to identify the characteristics of support for pain management, orientation of approaches, and behavior change components and outcomes.

INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH (2023)

Article Clinical Neurology

Truncating Variants in RFC1 in Cerebellar Ataxia, Neuropathy, and Vestibular Areflexia Syndrome

Riccardo Ronco, Cecilia Perini, Riccardo Curro, Natalia Dominik, Stefano Facchini, Alice Gennari, Roberto Simone, Skye Stuart, Sara Nagy, Elisa Vegezzi, Ilaria Quartesan, Amar El-Saddig, Timothy Lavin, Arianna Tucci, Agnieszka Szymura, Luiz Eduardo Novis De Farias, Alexander Gary, Megan Delfeld, Priscilla Kandikatla, Nifang Niu, Sanjukta Tawde, Joseph Shaw, James Polke, Mary M. Reilly, Nick W. Wood, Emmanuele Crespan, Christopher Gomez, Jin Yun Helen Chen, Jeremy Dan Schmahmann, David Gosal, Henry Houlden, Soma Das, Andrea Cortese

Summary: This study expands the genotypic spectrum of CANVAS by identifying sequence variants in the RFC1-coding region. The findings provide diagnostic recommendations for CANVAS and shed further light on its pathogenesis.

NEUROLOGY (2023)

暂无数据